An otherwise active, healthy 39-year-old, Marisa Peters was a mother of three boys and still nursing her 16-month-old when she was initially diagnosed with Stage 3 rectal cancer.

Anita Turk, MD, discusses what she is most excited about regarding immunotherapy in the realm of colorectal cancer treatment.

Anita Turk, MD, discusses the unmet needs that still exist in the realm of colorectal cancer treatment and management.

Patients in a structured exercise program experienced a 37% lower risk of death and a 28% reduction in recurrence or ...

Lopez rang the bell after beating cancer, sharing what the fight taught him: "Don't wait. Get checked. It can save your life.

Why and how does exercise reduce cancer risk, and what should everyone know about incorporating exercise programs in their ...

Waiting about 9 months or more to rechallenge patients with amivantamab can improve outcomes in patients with colorectal cancer, data suggest.

Metformin use may enhance progression-free survival (PFS) in patients receiving first-line systemic therapy for patients with ...

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Bobbi Conner talks with MUSC's Dr. Thomas Curran about the latest research showing that a structured exercise program extends ...

Oxaliplatin is a common colon cancer chemotherapy drug which costs $3,000 to $6,000 per treatment — cheap in the context of cancer care. The drug delivers an overall 10-year survival boost of 5%.

Between 2009 and 2023, the phase 3 study enrolled 889 adults (median age, 61 years; 51% women) who had completed surgery and adjuvant chemotherapy for stage III (90%) or high-risk stage II (10% ...